SCHEMBL4746853

SCHEMBL4746853

CCCCCCCCCCN(CCCCN(CC1CC1CN(CCCCN(CC)S(=O)(=O)c1c(C)cc(C)cc1C)S(=O)(=O)c1c(C)cc(C)cc1C)S(=O)(=O)c1c(C)cc(C)cc1C)S(=O)(=O)c1c(C)cc(C)cc1C

nearest known ligand 0.39

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 2/20 0.36
KMT2A Q03164 6/20 0.34
MEN1 O00255 5/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
LMNA P02545 1/20 0.34
KDM4E B2RXH2 2/20 0.34
SERPINE1 P05121 1/20 0.34
ALDH1A1 P00352 1/20 0.34
VCAM1 P19320 1/20 0.33
THRB P10828 1/20 0.33
MCHR1 Q99705 1/20 0.33
MAPT P10636 1/20 0.33
HTT P42858 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4744059 0.99 KMT2A (0.35) CNR2KMT2AMEN1SMN1; SMN2LMNA
SCHEMBL4746051 0.95 KMT2A (0.37) CNR2KMT2AMEN1SMN1; SMN2LMNA
SCHEMBL14080613 0.87 KMT2A (0.41) CNR2KMT2AMEN1SMN1; SMN2LMNA
SCHEMBL14080566 0.87 KMT2A (0.41) CNR2KMT2AMEN1SMN1; SMN2LMNA
SCHEMBL14080627 0.87 KMT2A (0.41) CNR2KMT2AMEN1SMN1; SMN2LMNA
SCHEMBL14080720 0.86 CNR2 (0.41) CNR2KMT2AMEN1SMN1; SMN2LMNA
SCHEMBL4746052 0.85 THRB (0.35) CNR2KMT2AMEN1SMN1; SMN2LMNA
SCHEMBL7509603 0.84 CA1 (0.41) CNR2KMT2ALMNAKDM4ESERPINE1
SCHEMBL7509594 0.84 CA1 (0.41) CNR2KMT2ALMNAKDM4ESERPINE1
SCHEMBL7518577 0.84 CA1 (0.41) CNR2KMT2ALMNAKDM4ESERPINE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008112251-A1 CYCLOPROPYL-CONTAINING POLYAMINE ANALOGS AS DISEASE THERAPIES PROGEN PHARMACEUTICALS, INC. (US) 2008-09-18 WO disclosed